10,000 Shares in Edwards Lifesciences Co. (NYSE:EW) Bought by Intact Investment Management Inc.

Intact Investment Management Inc. purchased a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 10,000 shares of the medical research company’s stock, valued at approximately $762,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in EW. Nordea Investment Management AB grew its stake in shares of Edwards Lifesciences by 1,224.1% during the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock worth $123,261,000 after acquiring an additional 1,488,791 shares during the period. Telos Capital Management Inc. raised its position in shares of Edwards Lifesciences by 158.2% in the fourth quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock valued at $6,970,000 after purchasing an additional 56,000 shares during the period. Arlington Trust Co LLC lifted its stake in shares of Edwards Lifesciences by 5,092.4% during the 4th quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock valued at $938,000 after buying an additional 12,069 shares in the last quarter. Versor Investments LP boosted its holdings in Edwards Lifesciences by 83.3% in the 3rd quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock worth $311,000 after buying an additional 2,043 shares during the period. Finally, HealthInvest Partners AB purchased a new position in Edwards Lifesciences in the 4th quarter valued at approximately $1,587,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $86.43 on Monday. The company’s 50-day moving average is $90.28 and its two-hundred day moving average is $78.95. The firm has a market capitalization of $52.02 billion, a price-to-earnings ratio of 37.25, a PEG ratio of 4.28 and a beta of 1.05. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The business had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Analysts forecast that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the sale, the chief financial officer now owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the completion of the sale, the vice president now owns 173,849 shares of the company’s stock, valued at approximately $16,049,739.68. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock valued at $17,166,254 over the last quarter. 1.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

EW has been the topic of several recent analyst reports. Royal Bank of Canada raised their target price on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a report on Monday, April 15th. Oppenheimer upped their price objective on Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, March 18th. Mizuho increased their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Stifel Nicolaus increased their price target on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a report on Friday. Finally, Evercore ISI lowered their price objective on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a report on Friday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $92.71.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.